Literature DB >> 8275616

Decreased acetylation of isoniazid in chronic renal failure.

Y G Kim1, J G Shin, S G Shin, I J Jang, S Kim, J S Lee, J S Han, Y N Cha.   

Abstract

Pharmacokinetic parameters of isoniazid obtained from 37 normal subjects were compared with parameters obtained from 14 patients with chronic renal failure. In the 29 normal rapid acetylators and eight normal slow acetylators, the mean plasma half-life values of isoniazid were 1.54 +/- 0.31 and 3.68 +/- 0.59 hours, respectively. The plasma half-life values of isoniazid in patients with chronic renal failure varied widely from 1.30 to 10.13 hours, but the values were significantly longer than those of normal subjects. Because isoniazid clearance is governed mainly by hepatic metabolism, such a significant prolongation of plasma half-life of isoniazid was unexpected; thus the pharmacokinetics of isoniazid were reevaluated in the same patients with chronic renal failure after the kidney transplantation. After successful kidney transplantation, the shortening of isoniazid half-life was pronounced and the nonrenal clearance was markedly increased. These findings indicate that decreased isoniazid clearance in chronic renal failure is caused in minor part by the decreased renal excretion of isoniazid and in major part by the depressed hepatic N-acetylation of isoniazid.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8275616     DOI: 10.1038/clpt.1993.198

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

Review 2.  Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

3.  Downregulation of hepatic acetylation of drugs in chronic renal failure.

Authors:  Emilie Simard; Judith Naud; Josée Michaud; Francois A Leblond; Alain Bonnardeaux; Chantal Guillemette; Edith Sim; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

4.  Pharmacokinetics of quinine in patients with chronic renal failure.

Authors:  P Rimchala; J Karbwang; K Sukontason; V Banmairuroi; P Molunto; K Na-Bangchang
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 5.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

Review 6.  A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD.

Authors:  Thomas D Nolin
Journal:  Semin Dial       Date:  2015-04-08       Impact factor: 3.455

7.  Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450.

Authors:  Josée Michaud; Pierre Dubé; Judith Naud; Francois A Leblond; Karine Desbiens; Alain Bonnardeaux; Vincent Pichette
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

Review 8.  The effect of chronic renal failure on drug metabolism and transport.

Authors:  Albert W Dreisbach; Juan J L Lertora
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-08       Impact factor: 4.481

Review 9.  Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity.

Authors:  G R Matzke; R F Frye
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

10.  In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases.

Authors:  Melanie S Joy; Reginald F Frye; Thomas D Nolin; Brittney V Roberts; Mary K La; Jinzhao Wang; Kim L R Brouwer; Mary Anne Dooley; Ronald J Falk
Journal:  Pharmacotherapy       Date:  2013-09-06       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.